CARsgen completed enrollment in a pivotal Phase 2 trial of satricabtagene autoleucel (satri-cel), a CLDN18.2-targeted CAR-T therapy, for advanced gastric/gastroesophageal cancer.
A Phase I trial of TAC01-CLDN18.2 demonstrates promising safety and efficacy in heavily pre-treated gastric cancer patients with Claudin18.2 expression, showing disease control in 83% of assessed patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.